Stockhub

Vaxil Bio Ltd.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

10 August 2022

  • curprev 18:4918:49, 10 August 2022‎ Paris talk contribs‎ 806 bytes +806‎ Created page with "Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the compa..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Vaxil_Bio_Ltd.’